Spots Global Cancer Trial Database for retifanlimab
Every month we try and update this database with for retifanlimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | NCT04472429 | Squamous Cell C... | carboplatin paclitaxel retifanlimab | 18 Years - | Incyte Corporation | |
| Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | NCT06160206 | Recurrent Gliob... Recurrent WHO G... | Bevacizumab Biospecimen Col... Computed Tomogr... Electronic Heal... Hypofractionate... Magnetic Resona... Retifanlimab | 18 Years - | Academic and Community Cancer Research United | |
| A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) | NCT03599713 | Metastatic Merk... | Retifanlimab | 18 Years - | Incyte Corporation | |
| MGD009/MGA012 Combination in Relapsed/Refractory Cancer | NCT03406949 | Advanced Solid ... | obrindatamab retifanlimab | 18 Years - | MacroGenics | |
| A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) | NCT06389799 | Dedifferentiate... | Pemigatinib Retifanlimab | 18 Years - 100 Years | Lund University Hospital | |
| MGD009/MGA012 Combination in Relapsed/Refractory Cancer | NCT03406949 | Advanced Solid ... | obrindatamab retifanlimab | 18 Years - | MacroGenics | |
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | NCT04082364 | Gastric Cancer Gastroesophagea... HER2-positive G... | margetuximab Retifanlimab Tebotelimab Trastuzumab Chemotherapy | 18 Years - | MacroGenics | |
| A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) | NCT03597295 | Squamous Cell C... | Retifanlimab | 18 Years - | Incyte Corporation | |
| Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | NCT04472429 | Squamous Cell C... | carboplatin paclitaxel retifanlimab | 18 Years - | Incyte Corporation | |
| INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | NCT03589651 | Unresectable or... | Retifanlimab Epacadostat INCB050465 | 18 Years - | Incyte Corporation | |
| A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) | NCT03597295 | Squamous Cell C... | Retifanlimab | 18 Years - | Incyte Corporation | |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | NCT06149481 | Metastatic Colo... | Retifanlimab Therapeutic CEA... N-803 SX-682 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors | NCT03910530 | Advanced Solid ... Metastatic Soli... | Retifanlimab INCB001158 Retifanlimab + ... | 18 Years - | Incyte Corporation | |
| Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors | NCT06320405 | Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali... | Axatilimab Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Paclitaxel Positron Emissi... Retifanlimab | 18 Years - | OHSU Knight Cancer Institute | |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | NCT06149481 | Metastatic Colo... | Retifanlimab Therapeutic CEA... N-803 SX-682 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma | NCT06056895 | Unresectable Cl... Clinical Stage ... Merkel Cell Car... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Retifanlimab Tuparstobart Verzistobart | 18 Years - | University of Washington | |
| INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | NCT04445844 | Anatomic Stage ... Locally Advance... Metastatic Trip... Prognostic Stag... Triple-negative... | Pelareorep Quality-of-Life... Questionnaire A... Retifanlimab | 18 Years - | Rutgers, The State University of New Jersey | |
| INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | NCT04445844 | Anatomic Stage ... Locally Advance... Metastatic Trip... Prognostic Stag... Triple-negative... | Pelareorep Quality-of-Life... Questionnaire A... Retifanlimab | 18 Years - | Rutgers, The State University of New Jersey | |
| A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | NCT03679767 | Metastatic Non-... Locally Advance... Metastatic Urot... Unresectable Me... Metastatic Mela... Locally Advance... Metastatic Clea... | Retifanlimab | 18 Years - | Incyte Corporation | |
| Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | NCT05440942 | Pancreatic Duct... | Trametinib Ruxolitinib Retifanlimab | 18 Years - | University of Miami | |
| Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer | NCT04799431 | Pancreatic Canc... Colorectal Canc... | Neoantigen Vacc... Retifanlimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. | NCT04949191 | Advanced Malign... | Pemigatinib Retifanlimab Pembrolizumab | 18 Years - 90 Years | Incyte Corporation | |
| An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | NCT04586244 | Urothelial Carc... | retifanlimab epacadostat INCAGN02385 INCAGN02390 | 18 Years - | Incyte Corporation | |
| An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | NCT04586244 | Urothelial Carc... | retifanlimab epacadostat INCAGN02385 INCAGN02390 | 18 Years - | Incyte Corporation | |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | NCT05455697 | Diffuse Large B... Grade 3b Follic... High Grade B-Ce... | Bone Marrow Bio... Cyclophosphamid... Doxorubicin Prednisone Retifanlimab Rituximab and H... Tafasitamab Vincristine Bone Marrow Asp... Multigated Acqu... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Biospecimen Col... Polatuzumab Ved... | 18 Years - | University of Washington | |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | NCT06149481 | Metastatic Colo... | Retifanlimab Therapeutic CEA... N-803 SX-682 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | NCT04472429 | Squamous Cell C... | carboplatin paclitaxel retifanlimab | 18 Years - | Incyte Corporation | |
| Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | NCT05440942 | Pancreatic Duct... | Trametinib Ruxolitinib Retifanlimab | 18 Years - | University of Miami | |
| Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma | NCT06056895 | Unresectable Cl... Clinical Stage ... Merkel Cell Car... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Retifanlimab Tuparstobart Verzistobart | 18 Years - | University of Washington | |
| INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT05359692 | Metastatic Head... Advanced Malign... Recurrent Head ... | INCAGN01876 retifanlimab | 18 Years - 99 Years | Incyte Corporation | |
| Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | NCT04634825 | Head and Neck C... Head and Neck N... Head and Neck S... | Enoblituzumab Retifanlimab Tebotelimab | 18 Years - | MacroGenics | |
| A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | NCT03059823 | Locally Advance... Metastatic Soli... | retifanlimab | 18 Years - | Incyte Corporation | |
| Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma | NCT05083754 | Glioblastoma Mu... | Retifanlimab Temozolomide Radiation Thera... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | NCT06179160 | Solid Tumors | INCB161734 Cetuximab Retifanlimab | 18 Years - | Incyte Corporation | |
| Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | NCT06160206 | Recurrent Gliob... Recurrent WHO G... | Bevacizumab Biospecimen Col... Computed Tomogr... Electronic Heal... Hypofractionate... Magnetic Resona... Retifanlimab | 18 Years - | Academic and Community Cancer Research United | |
| Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | NCT04205812 | Metastatic Squa... Metastatic Nons... | Retifanlimab Placebo Pemetrexed Cisplatin Carboplatin Paclitaxel nab-Paclitaxel | 18 Years - | Incyte Corporation | |
| Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT05287113 | Head and Neck C... | Retifanlimab INCAGN02385 INCAGN02390 Placebo | 18 Years - 99 Years | Incyte Corporation | |
| Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT05287113 | Head and Neck C... | Retifanlimab INCAGN02385 INCAGN02390 Placebo | 18 Years - 99 Years | Incyte Corporation | |
| Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | NCT04205812 | Metastatic Squa... Metastatic Nons... | Retifanlimab Placebo Pemetrexed Cisplatin Carboplatin Paclitaxel nab-Paclitaxel | 18 Years - | Incyte Corporation | |
| Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome | NCT04776876 | Advanced Neuroe... Carcinoid Syndr... | Retifanlimab Telotristat Eth... | 18 Years - | M.D. Anderson Cancer Center | |
| INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) | NCT04203511 | Non-small Cell ... | Retifanlimab Placebo Pemetrexed Cisplatin Carboplatin Paclitaxel Etoposide Radiotherapy | 18 Years - | Incyte Corporation | |
| A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) | NCT03599713 | Metastatic Merk... | Retifanlimab | 18 Years - | Incyte Corporation | |
| Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | NCT04634825 | Head and Neck C... Head and Neck N... Head and Neck S... | Enoblituzumab Retifanlimab Tebotelimab | 18 Years - | MacroGenics | |
| Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery | NCT05594290 | Merkel Cell Car... | Retifanlimab Cisplatin Etoposide | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | NCT04370704 | Melanoma | INCAGN02385 INCAGN02390 INCMGA00012. | 18 Years - | Incyte Corporation | |
| All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | NCT05345002 | Glioma IDH Mutation Astrocytoma Oligodendroglio... | Retifanlimab All-trans retin... | 18 Years - | University of Pennsylvania | |
| INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT05359692 | Metastatic Head... Advanced Malign... Recurrent Head ... | INCAGN01876 retifanlimab | 18 Years - 99 Years | Incyte Corporation | |
| Combination Study of SV-BR-1-GM With Retifanlimab | NCT03328026 | Breast Cancer Breast Neoplasm Metastatic Brea... Breast Cancer M... | SV-BR-1-GM Low dose cyclop... Interferon Inoc... retifanlimab | 18 Years - | BriaCell Therapeutics Corporation | |
| Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma | NCT05083754 | Glioblastoma Mu... | Retifanlimab Temozolomide Radiation Thera... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | NCT03059823 | Locally Advance... Metastatic Soli... | retifanlimab | 18 Years - | Incyte Corporation | |
| Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery | NCT05594290 | Merkel Cell Car... | Retifanlimab Cisplatin Etoposide | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | NCT05455697 | Diffuse Large B... Grade 3b Follic... High Grade B-Ce... | Bone Marrow Bio... Cyclophosphamid... Doxorubicin Prednisone Retifanlimab Rituximab and H... Tafasitamab Vincristine Bone Marrow Asp... Multigated Acqu... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Biospecimen Col... Polatuzumab Ved... | 18 Years - | University of Washington | |
| Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | NCT02393248 | Lung Cancer Solid Tumor Gastric Cancer Urothelial Canc... Endometrial Can... Multiple Myelom... Myeloproliferat... Breast Cancer Cholangiocarcin... UC MPN | Pemigatinib Gemcitabine Pembrolizumab Docetaxel Trastuzumab Retifanlimab Cisplatin | 18 Years - | Incyte Corporation | |
| A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | NCT03679767 | Metastatic Non-... Locally Advance... Metastatic Urot... Unresectable Me... Metastatic Mela... Locally Advance... Metastatic Clea... | Retifanlimab | 18 Years - | Incyte Corporation | |
| Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | NCT04463771 | Endometrial Can... | retifanlimab epacadostat pemigatinib INCAGN02385 INCAGN02390 | 18 Years - | Incyte Corporation | |
| 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma | NCT05239182 | Pancreatic Aden... | 9-ING-41 Retifanlimab Gemcitabine Abraxane | 18 Years - | University of Pittsburgh |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
